US00461U1051
US00461U1051
Aclaris Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 7.826.000 | 18.720.000 | 58.2% |
| Cost of Revenue | 7.284.000 | 15.458.000 | 52.9% |
| Gross Profit | 542.000 | 3.262.000 | 83.4% |
| 74.617.000 | 55.789.000 | 33.7% | |
| Operating Income | -74.075.000 | -52.527.000 | 41.0% |
| Pretax Income | -64.923.000 | -132.065.000 | 50.8% |
| Net Income Common Stockholders | -64.923.000 | -132.065.000 | 50.8% |
| -- | -- | -- | |
| -- | -- | -- |